Introduction Locally advanced pancreatic cancer (LAPC) remains a highly lethal disease with limited therapeutic options and poor long-term survival. For patients who remain unresectable after induction chemotherapy, local ablative strategies such as radiofrequency ablation (RFA) have been explored as a means to improve local control, prolong survival and potentially enhance quality of life.
Introduction
Locally advanced pancreatic cancer (LAPC) remains a highly lethal disease with limited therapeutic options and poor long-term survival. For patients who remain unresectable after induction chemotherapy, local ablative strategies such as radiofrequency ablation (RFA) have been explored as a means to improve local control, prolong survival and potentially enhance quality of life.
Problem Statement
Although RFA has shown feasibility and encouraging outcomes in observational studies, high-quality randomized evidence supporting its use in LAPC has been lacking. Whether adding RFA to standard chemotherapy improves survival or symptom burden in patients with non progressive LAPC after induction chemotherapy has remained an important unanswered clinical question.
Summary
The PELICAN randomized clinical trial demonstrates that adding RFA to chemotherapy does not improve outcomes in patients with non progressive LAPC after induction chemotherapy. In this multicenter phase 3 trial, RFA combined with chemotherapy failed to improve overall survival or progression-free survival compared with chemotherapy alone. Importantly, the addition of RFA was associated with significantly more serious adverse events and consistently worse quality of life across multiple domains, including global health status, pain and digestive symptoms. These findings directly challenge prior observational data suggesting a benefit for local ablative therapy in LAPC and provide the strongest evidence to date against routine use of RFA in this setting. While RFA had been proposed as a strategy to improve local disease control or augment systemic therapy, this trial found no meaningful oncologic advantage and demonstrated clear treatment-related burden. The study strongly supports continued chemotherapy-based management as the preferred standard for unresectable LAPC after induction therapy and argues against the routine incorporation of RFA outside highly selected investigational settings.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.